{{Rsnum
|rsid=2912791
|Gene=FGFR2
|Chromosome=10
|position=123318961
|Orientation=minus
|GMAF=0.3696
|Gene_s=FGFR2
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 35.7 | 53.6 | 10.7
| HCB | 31.4 | 48.9 | 19.7
| JPT | 18.6 | 49.6 | 31.9
| YRI | 58.2 | 37.0 | 4.8
| ASW | 53.6 | 35.7 | 10.7
| CHB | 31.4 | 48.9 | 19.7
| CHD | 16.5 | 48.6 | 34.9
| GIH | 26.7 | 51.5 | 21.8
| LWK | 70.9 | 27.3 | 1.8
| MEX | 55.2 | 34.5 | 10.3
| MKK | 65.4 | 30.8 | 3.8
| TSI | 31.4 | 53.9 | 14.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=23232491
|Title=A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528
}}

{{PMID Auto
|PMID=18285324
|Title=Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}